(HealthDay News) — The mean time to resolution of axillary lymphadenopathy after a COVID-19 vaccine booster is 102 days, according to a study published in the American Journal of Roentgenology.
Researchers conducted a retrospective, single-institution study of 54 patients with unilateral axillary lymphadenopathy ipsilateral to a booster dose of an mRNA COVID-19 vaccine that was visualized on an ultrasound performed between Sept. 1, 2021, and Dec. 31, 2022. The patients were followed until lymphadenopathy resolution.
Six of the patients had a history of breast cancer, and 2 had symptoms related to the axillary lymphadenopathy (axillary pain). The lymphadenopathy resolved at a mean of 102 days after the booster dose and at 84 days after the initial ultrasound.
In univariable and multivariable analyses, there were no significant associations between time to resolution and age, vaccine booster type (Moderna vs Pfizer), or history of breast cancer. However, time to resolution was significantly shorter after a booster dose than after the first dose of the initial series (mean, 129 days).
“Axillary lymphadenopathy after a booster dose of a COVID-19 vaccine required a mean of 102 days to show resolution on follow-up ultrasound examinations,” the researchers wrote. “This duration supports application in the setting of booster doses of the current recommendation for a follow-up interval of at least 12 weeks, as well as avoidance of screening mammography delays, for suspected vaccine-related lymphadenopathy.”
Abstract/Full Text (subscription or payment may be required)